Guilin Sanjin Pharmaceutical Co Ltd Class A 002275
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥14.46
- Day Range
- ¥14.71–15.66
- 52-Week Range
- ¥11.28–18.35
- Bid/Ask
- ¥15.52 / ¥15.53
- Market Cap
- ¥9.12 Bil
- Volume/Avg
- 7.5 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 29.76
- Price/Sales
- 4.46
- Dividend Yield (Trailing)
- 3.87%
- Dividend Yield (Forward)
- 3.87%
- Total Yield
- 3.87%
Company Profile
Guilin Sanjin Pharmaceutical Co Ltd is engaged in research and development of proprietary Chinese medicines and natural medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,615
- Website
- http://www.sanjin.com.cn
Comparables
Valuation
Metric
|
002275
|
300142
|
603896
|
---|---|---|---|
Price/Earnings (Normalized) | 29.76 | 78.48 | 20.69 |
Price/Book Value | 3.11 | 2.49 | 2.25 |
Price/Sales | 4.46 | 6.97 | 6.33 |
Price/Cash Flow | 18.86 | 21.71 | 13.42 |
Price/Earnings
002275
300142
603896
Financial Strength
Metric
|
002275
|
300142
|
603896
|
---|---|---|---|
Quick Ratio | 2.75 | 2.51 | 3.21 |
Current Ratio | 3.31 | 2.94 | 3.70 |
Interest Coverage | 24.06 | 24.73 | 16.62 |
Quick Ratio
002275
300142
603896
Profitability
Metric
|
002275
|
300142
|
603896
|
---|---|---|---|
Return on Assets (Normalized) | 7.55% | 1.93% | 7.55% |
Return on Equity (Normalized) | 9.98% | 3.16% | 11.00% |
Return on Invested Capital (Normalized) | 8.16% | 2.01% | 7.10% |
Return on Assets
002275
300142
603896
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Wdwwnpwlz | Wlrw | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Wxgptjb | Gplbdz | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Jvfrvngg | Dzdgmp | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Gkjnqslxk | Gbfcmc | $34.4 Bil | |||
argenx SE ADR
ARGX
| Dryfcnkp | Qcwr | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Bhknnvtbs | Fwsc | $29.2 Bil | |||
Moderna Inc
MRNA
| Hbwhrfbx | Bbc | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Jrqzlyfq | Qnjrc | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Ljcxjyjr | Wqxfvnn | $13.2 Bil | |||
Incyte Corp
INCY
| Wscctxl | Pkbltnm | $13.0 Bil |